ENSP is an international non-profit association, created in 1997 under Belgium law, which aims to reduce tobacco consumption & to develop a common strategy amongst organisations active in tobacco control throughout Europe, by sharing information & experience, through co-ordinated activities & projects, by creating synergies among public health advocates thus increasing their capacity to direct their actions more effectively. ENSP acts as the lynchpin for its members creating a central cohesive force for the European tobacco control movement.
ENSP`s vision for the future is to eliminate the suffering of European citizens caused by ill health & early death due to tobacco-related diseases. We want children & young people to be able to grow up without being targets of tobacco industry marketing seeking to lure them into a lifetime of addiction. We want clean air unpolluted by tobacco smoke for all European citizens. ENSP`s strategic goal is to make our continent completely smoke-free by 2040 & our first objective is to work towards full implementation of the FCTC in Europe by 2020.
Given that tobacco control is at different stages in different European countries, ENSP applies the best & most effective evidence in policy & practice to work together towards a shared goal. ENSP members can take advantage of past experience in other countries & adapt such experience to their own needs. ENSP members work together to agree on a common policy & speak together in one voice, thus strengthening the European tobacco control effort & reinforcing European public health messages.
To eliminate the use of tobacco products in Europe, ENSP believes above all that all European countries need to implement comprehensive tobacco control strategies, including high taxes, comprehensive bans on direct & indirect advertising of tobacco, smoking bans in public & all workplaces, introduce strong & large (80%) textual & pictorial warnings on standardised tobacco packages.



Measures of mortality are among the most important indicators for public health. All European Union member states collect all-cause mortality data in order to facilitate planning, monitoring annual trends of diseases and evaluating public health interventions. However, there is little tradition of conducting timely monitoring of mortality. This lack of timely collection, analysis and interpretation is a limitation when it comes to the assessment of the health impact of events that may lead to sudden changes in mortality such as major epidemics, extreme temperatures as well as deliberate or accidental release of biological or chemical agents.
In the DG Sanco supported project EuroMOMO we developed a coordinated approach to real-time mortality monitoring across Europe. This system is ready to apply among countries that are able to meet the minimal requirements for mortality monitoring. Currently, the weekly output (the mortality bulletin at www.euromomo.eu) is based on data submitted from 15 countries.
The EuroMOMO network demonstrated how a timely, standardised and coordinated approach to mortality monitoring increases the European capacity to assess the impact of events with a potential impact on public health, including the 2009/10 influenza A(H1N1) pandemic. Without EuroMOMO, Europe would have been less well prepared for the pandemic
In addition, EuroMOMO was pivotal to facilitate country-specific in-depth analyses of influenza-associated mortality in general or the impact of the pandemic more specifically.
Our mission is to reinforce the EU`s preparedness to respond to potential risk by a continued operation of the EuroMOMO network. The vision is further to extent the collaboration by adding new countries to the network. By training activites, partners will learn and exchange best practice on how to apply data from real-time mortality monitoring for risk assessment, in particular as regards cross-border threats and the management of the public health response to emergencies.


Measures of mortality are among the most important indicators for public health. All European Union member states collect all-cause mortality data in order to facilitate planning, monitoring annual trends of diseases and evaluating public health interventions. However, there is little tradition of conducting timely monitoring of mortality. This lack of timely collection, analysis and interpretation is a limitation when it comes to the assessment of the health impact of events that may lead to sudden changes in mortality such as major epidemics, extreme temperatures as well as deliberate or accidental release of biological or chemical agents.
In the DG Sanco supported project EuroMOMO we developed a coordinated approach to real-time mortality monitoring across Europe. This system is applied among countries that are able to meet the minimal requirements for mortality monitoring. Currently, the weekly published EuroMOMO mortality bulletin at www.euromomo.eu is based on data submitted from 18 countries or regions of countries.

The EuroMOMO network demonstrated how a timely, standardised and coordinated approach to mortality monitoring increases the European capacity to assess the impact of events with a potential impact on public health, including the 2009/10 influenza A(H1N1) pandemic. Without EuroMOMO, Europe would have been less well prepared for the pandemic
In addition, EuroMOMO was pivotal to facilitate country-specific in-depth analyses of influenza-associated mortality in general or the impact of the pandemic more specifically.
Our mission is to reinforce the EU`s preparedness to respond to potential risk of all hazards by a continued operation of the EuroMOMO network. The vision is further to extend the collaboration by adding new countries to the network.
By conducting regular network activites, partners will learn and exchange best practice on how to apply data from real-time mortality monitoring for risk assessment, in particular as regards cross-border threats and the management of the public health response to emergencies.


To assess the feasibility and effectiveness of programs designed to detect and manage frail older patients in high risk clinical settings, and to avoid functional impairment and other associated adverse outcomes. These high risk settings will be medical wards (cardiology, oncology/oncohaematology or nephrology), major surgery wards and Emergency Rooms.
As a consequence, our main aim is to improve the poor outcomes of frail older people previously undetected in settings of high risk. These main poor outcomes include functional decline, institutionalization, hospitalization and death, but also under/over or mismanagement driving to avoidable secondary effects of treatment among which include denial of treatment solely on the basis of age or, by opposite, overly aggressive handling for frail patients. This pathway of care should have a relevant impact on the sustainability of health and social systems by preventing functional decline (one of the culprits of the high costs)and avoiding unnecessary interventions and their undesired secondary effects.

